Published in Mol Cancer on April 06, 2011
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal (2013) 1.17
The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol (2012) 1.14
Targeting survivin in cancer: novel drug development approaches. BioDrugs (2014) 0.98
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription. Mol Cancer (2014) 0.96
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia (2013) 0.94
MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res (2014) 0.93
Prognostic relevance of survivin in pancreatic endocrine tumors. World J Surg (2012) 0.91
TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med (2012) 0.90
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol (2014) 0.89
Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch (2012) 0.86
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res (2013) 0.86
CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell (2014) 0.85
Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered (2012) 0.85
Survivin: a unique target for tumor therapy. Cancer Cell Int (2016) 0.84
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). PLoS One (2013) 0.82
Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J Cancer Res Clin Oncol (2012) 0.82
Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett (2015) 0.82
The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer. PLoS One (2013) 0.81
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs (2013) 0.81
Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One (2013) 0.80
Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines. Bioorg Med Chem (2014) 0.79
Localization and upregulation of survivin in cancer health disparities: a clinical perspective. Biologics (2015) 0.79
Loss of Survivin influences liver regeneration and is associated with impaired Aurora B function. Cell Death Differ (2013) 0.79
Bifunctional roles of survivin-ΔEx3 and survivin-2B for susceptibility to apoptosis in endometrial carcinomas. J Cancer Res Clin Oncol (2014) 0.79
A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. Cell Death Dis (2014) 0.78
Transcriptional upregulation of HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Invest (2015) 0.77
IWR-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing Wnt/β-catenin signaling as well as survivin expression. Oncotarget (2015) 0.77
Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma. Bosn J Basic Med Sci (2015) 0.76
Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants. Eur J Nutr (2015) 0.76
Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo. Cancer Gene Ther (2015) 0.76
miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells. Mol Cancer (2016) 0.75
Survivin small interfering RNA suppresses glioblastoma growth by inducing cellular apoptosis. Neural Regen Res (2012) 0.75
Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist. Mol Ther Oncolytics (2016) 0.75
Pro-apoptotic effects of rHSG on C6 glioma cells. Int J Mol Med (2016) 0.75
Survivin: a new player during erythroblast maturation. Haematologica (2012) 0.75
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
Proteases to die for. Genes Dev (1998) 5.43
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 4.52
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer (2004) 3.76
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol (2004) 3.49
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis (2007) 3.16
Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci (2001) 3.03
Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol (2000) 2.85
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res (2007) 2.80
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004) 2.59
Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut (2000) 2.56
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J (2003) 2.47
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res (1998) 2.38
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol (2003) 2.30
Survivin and molecular pathogenesis of colorectal cancer. Lancet (2003) 2.25
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res (1999) 2.21
The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol (2006) 2.19
Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res (2004) 2.19
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology (2000) 2.15
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer (2001) 2.10
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene (2000) 2.04
A p34(cdc2) survival checkpoint in cancer. Cancer Cell (2002) 1.99
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res (1999) 1.89
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol (1998) 1.84
Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med (2003) 1.83
Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep (2006) 1.82
Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A (2004) 1.79
Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell (2000) 1.77
Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res (2005) 1.76
Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer (2001) 1.75
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol (2003) 1.73
Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer (2001) 1.73
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol (2009) 1.66
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65
Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer (2002) 1.62
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
The case for Survivin as mitotic regulator. Curr Opin Cell Biol (2006) 1.59
Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun (2004) 1.58
Hsp60 regulation of tumor cell apoptosis. J Biol Chem (2007) 1.57
Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res (2003) 1.54
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene (2004) 1.54
Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma (2007) 1.54
Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res (2009) 1.51
Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis (2007) 1.50
Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat (2002) 1.49
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47
XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene (2004) 1.44
Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res (2000) 1.43
Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem (2004) 1.36
Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res (2008) 1.35
Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res (2004) 1.33
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer (2003) 1.33
Retracted Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett (2002) 1.30
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol (2001) 1.27
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol (2004) 1.26
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer (2005) 1.26
Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys (2003) 1.22
The chromosomal passenger complex: one for all and all for one. Cell (2007) 1.22
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques (2004) 1.21
Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol (2002) 1.19
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A (2004) 1.16
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer (2005) 1.16
Survivin does not inhibit caspase-3 activity. Blood (2000) 1.15
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep (2005) 1.12
Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res (2002) 1.11
Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol (2008) 1.07
Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett (2008) 1.06
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine (2005) 1.05
Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem (2006) 1.05
Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther (2007) 1.04
Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. Int J Gynecol Cancer (2005) 1.01
Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer (2002) 1.00
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol (2003) 1.00
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene (2003) 0.99
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol (2004) 0.98
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther (2006) 0.96
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Thinning of the cerebral cortex in aging. Cereb Cortex (2004) 8.31
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci (2007) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A (2003) 5.64
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord (2007) 5.01
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex (2004) 3.87
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry (2009) 3.72
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol (2005) 3.69
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology (2009) 3.56
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Under-recruitment and nonselective recruitment: dissociable neural mechanisms associated with aging. Neuron (2002) 3.18
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ (2013) 3.05
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol (2006) 3.00
APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci (2010) 2.99
The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology (2008) 2.91
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage (2003) 2.77
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol (2005) 2.76
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol (2008) 2.67
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Validity and reliability of the AD8 informant interview in dementia. Neurology (2006) 2.42
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol (2008) 2.40
Longitudinal driving performance in early-stage dementia of the Alzheimer type. J Am Geriatr Soc (2003) 2.37
Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology (2002) 2.34
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry (2006) 2.29
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type. IEEE Trans Med Imaging (2007) 2.24
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Clinical phenotype of Parkinson disease dementia. Neurology (2006) 2.22
Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage (2005) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol (2005) 2.11
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging (2007) 2.09
Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry (2006) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology (2007) 2.06
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Prediction of on-road driving performance in patients with early Alzheimer's disease. J Am Geriatr Soc (2005) 2.03
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex (2004) 1.91
Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord (2004) 1.91
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol (2011) 1.87
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol (2006) 1.80
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab (2003) 1.77
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77